Skip to content

Evaluation of the application of XYZ-110 electronic sphygmomanometer in blood pressure measurement in pregnant women

Evaluation of the application of XYZ-110 electronic sphygmomanometer in blood pressure measurement in pregnant women

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041455
Enrollment
Unknown
Registered
2020-12-26
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Gold Standard:Mercury sphygmomanometers

Sponsors

Huai'an First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Pregnant women aged over 20 in the second or third trimester of pregnancy; (2) Sign the informed consent; (3) At a stable clinical stage, language communication can be carried out smoothly.

Exclusion criteria

Exclusion criteria: (1) Subjects request to withdraw from the clinical trial; (2) The arm circumference exceeds the allowable range of the cuff of the blood pressure monitor; (3) Suffering from acute pain or clinical instability; (4) The wound on the upper arm is not healed or the upper arm is missing; (5) In the study, it was found that factors such as arrhythmia interfered with the accurate measurement of blood pressure using the reference method (auscultation method); (6) Patients with bilateral upper limb artery occlusion; (7) patients with mental illness and those who have no self-knowledge and cannot accurately express themselves; (8) Disease investigators who are not considered fit to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
blood pressure;

Countries

China

Contacts

Public ContactWang Bingjian

Huai'an First People's Hospital

81370019@qq.com+86 13861572900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026